Stapling the stomach of an obese child is a last resort, but the National Institute for Health and Clinical Excellence (NICE) has issued a stamp of approval for bariatric surgery as part of a national guideline aimed at reducing obesity in children and minimizing the long-term adverse health effects that being overweight has on health.

This is the NICE organization's effort to find solutions to England's rising obesity epidemic where the number of overweight and obese people in the last quarter century has tripled.

Stomach stapling is not the only solution, but it is now an approved option. Other recommendations include the following: local authorities working with local partners, such as industry and voluntary organizations, to create safe spaces for physical activity; providing cycling and walking routes, cycle parking, area maps and safe play areas; creating pedestrian-friendly streets; designing building and spaces to encourage more physical activity; requiring schools to provide an environment that promotes healthy eating and physical exercise; healthcare professionals taking the time to educate and give advice on how to maintain a healthy weight; raising public awareness and encouraging daily physical activities such as walking, cycling, swimming, aerobics or gardening.

Obesity cannot go unchecked and it is a threat to the health and welfare of children and adults alike, as obesity is linked to greater increased risks for a number of life-threatening diseases like heart disease, diabetes and cancer. But, it is uncomfortable to think that one of the solutions to childhood obesity is a scalpel. The NICE press release New NICE guideline calls for urgent action to stem the rising tide of obesity in England and Wales is available as a pdf document here.

I feel fortunate to have received every cancer drug I needed to fight my breast cancer -- Adriamycin, Cytoxan, Herceptin, and every nausea pill, pain capsule, and anti-anxiety formula on the market. I got exactly what doctors thought I needed -- without worry about availability or funding or politics. I am lucky. Some in the UK are not so lucky.

Two targeted therapies for bowel cancer will not be used in Britain's state-run health system, according to NICE -- the National Institute for Health and Clinical Excellence. NICE, the country's financial watchdog, determined the high cost of the medicines meant their use was not compatible with the best use of resources. Patients are angry because these same two drugs -- Avastin and Erbitux -- are used widely in the United States and in much of Europe. And while neither drug offers a cure for bowel cancer, both treatments have been shown in clinical trials to extend life expectancy by four or five months in some patients.

Based on doses given during the trials, it is estimated that the average cost of treating one patient with Avastin would be around 16,800 pounds and with Erbitux -- about 11,700 pounds. Apparently, this is too much. But according to Hilary Whittaker of the charity Beating Bowel Cancer, the decision to deprive patients of this medication is a scandal. I agree. And for these patients, I am sad.